These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25114058)

  • 21. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
    Hetland ML; Haavardsholm EA; Rudin A; Nordström D; Nurmohamed M; Gudbjornsson B; Lampa J; Hørslev-Petersen K; Uhlig T; Grondal G; Østergaard M; Heiberg MS; Twisk J; Lend K; Krabbe S; Hyldstrup LH; Lindqvist J; Hultgård Ekwall AK; Grøn KL; Kapetanovic M; Faustini F; Tuompo R; Lorenzen T; Cagnotto G; Baecklund E; Hendricks O; Vedder D; Sokka-Isler T; Husmark T; Ljoså MA; Brodin E; Ellingsen T; Söderbergh A; Rizk M; Olsson ÅR; Larsson P; Uhrenholt L; Just SA; Stevens DJ; Laurberg TB; Bakland G; Olsen IC; van Vollenhoven R;
    BMJ; 2020 Dec; 371():m4328. PubMed ID: 33268527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.
    Wells G; Becker JC; Teng J; Dougados M; Schiff M; Smolen J; Aletaha D; van Riel PL
    Ann Rheum Dis; 2009 Jun; 68(6):954-60. PubMed ID: 18490431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology.
    van Gestel AM; Anderson JJ; van Riel PL; Boers M; Haagsma CJ; Rich B; Wells G; Lange ML; Felson DT
    J Rheumatol; 1999 Mar; 26(3):705-11. PubMed ID: 10090187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Under-reporting of socio-economic status in randomized control trials of biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
    Chiu H; Hollingworth S; Van Driel M; Magin P; Benham H
    Rheumatology (Oxford); 2017 Apr; 56(4):660-661. PubMed ID: 28039418
    [No Abstract]   [Full Text] [Related]  

  • 25. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologic interventions for fatigue in rheumatoid arthritis.
    Almeida C; Choy EH; Hewlett S; Kirwan JR; Cramp F; Chalder T; Pollock J; Christensen R
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD008334. PubMed ID: 27271314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
    Colebatch AN; Marks JL; Edwards CJ
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008872. PubMed ID: 22071858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
    van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
    Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving rheumatoid arthritis comparative effectiveness research through causal inference principles: systematic review using a target trial emulation framework.
    Zhao SS; Lyu H; Solomon DH; Yoshida K
    Ann Rheum Dis; 2020 Jul; 79(7):883-890. PubMed ID: 32381560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.
    Aletaha D; Landewe R; Karonitsch T; Bathon J; Boers M; Bombardier C; Bombardieri S; Choi H; Combe B; Dougados M; Emery P; Gomez-Reino J; Keystone E; Koch G; Kvien TK; Martin-Mola E; Matucci-Cerinic M; Michaud K; O'Dell J; Paulus H; Pincus T; Richards P; Simon L; Siegel J; Smolen JS; Sokka T; Strand V; Tugwell P; van der Heijde D; van Riel P; Vlad S; van Vollenhoven R; Ward M; Weinblatt M; Wells G; White B; Wolfe F; Zhang B; Zink A; Felson D; ;
    Arthritis Rheum; 2008 Oct; 59(10):1371-7. PubMed ID: 18821648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations.
    Gaujoux-Viala C; Gossec L
    Ann N Y Acad Sci; 2014 May; 1318():32-40. PubMed ID: 24827544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials.
    Vashisht P; Sayles H; Cannella AC; Mikuls TR; Michaud K
    Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1478-88. PubMed ID: 26866293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
    Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
    Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
    Clark W; Jobanputra P; Barton P; Burls A
    Health Technol Assess; 2004 May; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update.
    Singh JA; Cameron DR
    J Manag Care Pharm; 2012 May; 18(4 Supp C):S1-18. PubMed ID: 22656072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect size in clinical studies of patients with rheumatoid arthritis. EULAR guidelines and OMERACT core-sets].
    Sangha O
    Z Rheumatol; 2000 Feb; 59(1):45-9. PubMed ID: 10769424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trials: how to cope with medical needs, ethics and timelines.
    Rubbert-Roth A; Burmester GR
    Ann Rheum Dis; 2010 Jan; 69(1):1-3. PubMed ID: 20007619
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.